AI-generated summary
The authors compared oral tofacitinib citrate plus 308-nm excimer laser with methylprednisolone in 63 patients with progressive vitiligo over 24 weeks. They report that combined tofacitinib and laser was faster-acting than the other arms, with no serious adverse reactions. The study is a pilot, so the authors describe the approach as potentially optimal rather than established.
- Participants
- 63
- Who or what was studied
- Patients with progressive vitiligo and a Vitiligo Disease Activity Score of 4, enrolled January 2022 to January 2024
- Wavelengths
- 308 nm
- Limits stated in the abstract
- The abstract describes this as a pilot study and does not report a control arm receiving no treatment or long-term follow-up beyond 24 weeks.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on academic.oup.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Pilot study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.